key: cord-0700975-0nho2jpv
authors: Zhou, Zhi-Guo; Jiang, Di-Xuan; Xie, Shu-Min; Zhang, Jing; Zheng, Fang; Peng, Hong; Chen, Xuan; Liu, Ji-Yang; Zhang, Lei
title: Low-dose corticosteroid combined with immunoglobulin reverses deterioration in severe cases with COVID-19
date: 2020-11-24
journal: Signal Transduct Target Ther
DOI: 10.1038/s41392-020-00407-0
sha: 957fee4895afefc00d05daa41938aefd5cb38213
doc_id: 700975
cord_uid: 0nho2jpv

nan

level. In terms of inflammation-related biomarkers, CRP (P < 0.05) was improved. The complete blood count, including leukocytes, neutrophils, and platelets increased significantly after treatment (P < 0.05). The liver and kidney function tests including albumin, alanine aminotransferase (ALT), aspartate aminotransferase (AST), total bilirubin (TBIL), and creatinine were significantly improved (P < 0.05). The myocardial enzymes, creatine kinase (CK), and lactate dehydrogenase (LDH) was significantly lower than the peak value (P < 0.05). In terms of oxygenation index, SPO 2 , PaCO 2 , and lactic acid were all significantly improved (P < 0.05) (Supplementary Table S2 ).

The common early pulmonary CT findings of COVID-19 infected patients showed multiple small, patchy infiltrates and interstitial changes in bilateral lungs; this progressed to bigger infiltrates with ground glass appearance in some cases. Pleural effusion was rare. A typical pulmonary CT series of severe case is displayed in Fig.  1f -j. Re-examination of the pulmonary CT of the 40 severe cases showed that the lung lesions improved in 36 cases, were stable in two cases, and deteriorated in only two cases. As of March 14th, a total of 237 cases in this study were discharged. Only two deaths occurred in our study; the probable cause of one death was cardiac failure secondary to acute myocardial injury (Supplementary Table S3 ).

As a double-edged sword in the treatment of viral pneumonias, corticosteroids must be administered properly and precisely. 2 Instead of conventional strategy of administrating corticosteroid in the final stages of a viral pneumonia, we believe that early lowdose corticosteroid therapy should be under consideration when clinical data indicates the progression of COVID-19. The relatively mild inflammatory response in the early stage of COVID-19 pneumonia allows low-dose of corticosteroid to control the progression of inflammation. 2 In our study, this therapy successfully reversed deterioration in most severe cases as shown by the significant improvement in multiple clinical indicators, including respiratory and oxygenation indicators, laboratory indicators, pulmonary imaging, and, most importantly, by the overall decreased mortality. Zheng et al. also reported that low-dose methylprednisolone reduced clinical manifestations of COVID-19 in severely ill patients and lowered the risk of death for those who developed ARDS. 3 According to our experience, the administration dose, timing, and duration should be determined according to clinical indicators including SPO 2 , body temperature, lymphocyte count, and progression in pulmonary CT.

Besides, we strongly recommend the combined use of immunoglobulin with corticosteroid, which could strengthen the patients' immune response to win us a relatively safer and longer timeframe for corticosteroid therapy. Immunoglobulin plays an assistant role through controlling the systemic inflammation, reducing lung viral load, and avoiding complications including secondary infection caused by corticosteroid immunosuppression. 4 Recent retrospective cohort study of 46 severe COVID-19 patients also showed promising results from the combination therapy, with great improvement in oxygen saturation, hospitalization, ICU time, and CT. 5 In this research, we formally proposed for the first time that combination of low-dose corticosteroid and immunoglobulin can be used to treat severe cases with COVID-19, which not only can reduce the effect of inflammatory storm caused by COVID-19 infection through low-dose corticosteroid, but also can improve the passive immunity and reduce the risk of secondary infections through immunoglobulin, thereby significantly reducing the overall mortality rate and morality rate of severe cases. Our research is of great significance in establishing the important position of low-dose corticosteroid in the treatment of COVID-19, and proposing an innovative combination treatment strategy of low-dose corticosteroid and immunoglobulin. We call for relevant clinical trials to further confirm the effectiveness of this treatment in COVID-19 severe cases. Fig. 1 a-e Trendgraph of important clinical variables of 40 severe cases respecting to the low-dose corticosteroid combined with immunoglobulin. a PaO 2 /FiO 2 , b temperature, c lymphocyte, d CRP, e APACHE II score. f-j A dynamic series of pulmonary CT imaging manifestation of a severe case. Multiple patchy, ground glass, and infiltrating shadows in bilateral lungs on hospital admission. During the treatment, the follow-up CT changes presented an improvement type (the imaging lesions continually absorbed). f The day before treatment with low-dose corticosteroid combined with immunoglobulin, g the 4th day of treatment, h the 9th day of treatment, i the 13th day of treatment, j the 3rd day after treatment Letter

On the use of corticosteroids for 2019-nCoV pneumonia

Risk-adapted treatment strategy for COVID-19 patients

Use of human immunoglobulins as an anti-infective treatment: the experience so far and their possible re-emerging role

A retrospective cohort study of methylprednisolone therapy in severe patients with COVID-19 pneumonia

This study was funded by the Innovative Major Emergency Project Funding against the New Coronavirus Pneumonia in Hunan Province (number 2020SK3014), Health and Family Planning Commission Fund Project in Hunan Province (number B2017209), Natural Science Foundation of Hunan Province (number 2018JJ2452). We thank all patients involved in the study. We thank Aleksandra Szymanska for critically revising the manuscript.

All data generated during this study are included in this published article and its supplementary information files.Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons. org/licenses/by/4.0/.